Sutro Biopharma (STRO) Total Liabilities (2016 - 2025)

Sutro Biopharma has disclosed Total Liabilities across 10 years of filings, most recently posting $306.3 million for Q4 2025.

• Total Liabilities for Q4 2025 came in at $306.3 million, down 10.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $306.3 million (down 10.6% YoY), and the FY2025 annual result was $306.3 million, down 10.6% from the prior year.
• Total Liabilities came in at $306.3 million for Q4 2025 at Sutro Biopharma, up from $296.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $347.2 million in Q1 2025 to a low of $51.2 million in Q1 2021.
• The 5-year median for Total Liabilities is $295.7 million (2025), against an average of $229.7 million.
• Across the five-year window, Total Liabilities decreased 28.69% in 2021 and jumped 237.67% in 2022, its largest moves.
• Sutro Biopharma's Total Liabilities stood at $88.8 million in 2021, then jumped by 113.74% to $189.9 million in 2022, then soared by 69.09% to $321.1 million in 2023, then grew by 6.7% to $342.6 million in 2024, then dropped by 10.6% to $306.3 million in 2025.
• The last three Total Liabilities figures came in at $306.3 million (Q4 2025), $296.9 million (Q3 2025), and $294.5 million (Q2 2025), per Business Quant data.